

# 9<sup>TH</sup> NORDIC PSYCHIATRY ACADEMY




## Adherence to Psychosis treatment – Removing the Roadblocks



With the support of:

**janssen**  
PHARMACEUTICAL COMPANIES  
OF *Johnson & Johnson*





# Content

Welcome greetings	4
Program	5
Scientific Committee	6
Speakers	8
Brainstorming Session	16



# Dear Colleague,

We are delighted to welcome You 9<sup>th</sup> Nordic Psychiatry Academy. It is a great pleasure to meet you at the Satellite Symposium entitled "Removing the Roadblocks: How can we meet Adherence challenge to Psychosis treatment in the future"

This educational meeting will bring together a group of leading experts and psychiatrists from the Nordic countries to learn, meet, discuss and share their knowledge of the current data and information regarding the effective treatment of psychosis.

The theme of this event strives to highlight and give the delegates tools to tackle non Adherence to medication in daily clinical practice, how to build a collaborative relationship with the mentally ill person they are trying to engage in treatment.

Today's presentations will look at ways to optimize treatment outcomes for patients with psychosis. Topics covered include challenges to tackle, pharmaceutical options and clinical perspective to improving Adherence. Lively interactive session lead by Nordic experts will give you an opportunity learn and discuss methods to improve treatment for schizophrenia in real-life settings. Xavier Amador from USA will give a keynote lecture on "I am not sick I don't need help". The day will close with panel discussion involving all members of the faculty. You are encouraged to participate to discussion during interactive sessions and submitting questions for the panel using the cards provided.

On behalf of the scientific Committee, we hope that You find this meeting highly informative and rewarding. We are confident that the insight gained throughout the day will assist You in meeting the clinical needs of your patients with schizophrenia.

**Anders Gaasland**, Norway; **Anders Berntsson**, Sweden;  
**Cecilia Brain**, Sweden; **Olli Kampman**, Finland.

# Program

**START 08.00–08.30 (REGISTRATION)**

**Chairman:** Ole Andreassen, Norway

Time	Topic	Speakers
08.30	Welcome and Introduction	Ole Andreassen, Norway
08.45	Removing the Roadblocks. How to overcome the barriers to the Adherence challenge	Cecilia Brain, Sweden
09.30	Antipsychotic drug treatment and Adherence	Hannu Koponen, Finland
10.15	Coffee	
10.45	Detecting and preventing non Adherence in the clinic	Werner Kissling, Germany
11.30	Question and answer session, Debate	All
12.00	Lunch	
13.00	<b>Brainstorming session part 1</b> How do we remove the roadblocks – Adherence challenges 1–4  Adherence challenge 1: How to deal with substance abuse in schizophrenia?  Adherence challenge 2: How do we organize our care indoor/outdoor for the patient with psychotic diseases for best Adherence? Especially for the first episode patient  Adherence challenge 3: How can we better help the patient when someone lacks insight and cognitive disturbances?  Adherence challenge 4: Do we stumble over stigma in our daily practice or do we contribute to a fresh new set of positive attitudes to schizophrenia?	Olli Kampman, Anders Berntsson, Ole Andreassen, Cecilia Brain, Anders Gaasland
13.45	Coffee	
14.15	<b>Brainstorming session part 2</b> Interactive Debate and Presentations	All
15.15	I'm not sick I don't need help	Xavier Amador, USA
16.15	Question and answer session, Debate	All
16.45	Summary and Close	Ole Andreassen, Norway

Attendance is by invitation only for psychiatrists.



# Scientific Committee



Cecilia Brain, Sweden

Cecilia Brain, M.D., doctoral candidate, Department of Psychiatry and Neurochemistry. The Sahlgrenska Academy, University of Gothenburg.

Senior consultant, specialist in psychiatry Sahlgrenska University Hospital, Göteborg, Sweden.



Anders Berntsson, Sweden

Anders Berntsson, MD, specialist in psychiatry. Director PRIMA Adult Psychiatry.

Stockholm NO, Sweden

[anders.berntsson@primavuxen.se](mailto:anders.berntsson@primavuxen.se)



Anders Gaasland, Norway

Anders Gaasland, Chief Psychiatrist at Tøyen DPS – Outward Clinic at Lovisenberg Hospital in Oslo.



Olli Kampman, Finland

Adjunct professor in Department of Psychiatry, University of Tampere since 2000.

Psychotherapist (cognitive-behavioral therapy).

Scientific publications on adherence in psychoses and pharmacogenetics in schizophrenia and depression.



## Moderator

Ole Andreassen, Professor in psychiatry at Institute of Clinical Medicine, University of Oslo and attending psychiatrist, Oslo University Hospital, Oslo, Norway.

Ole Andreassen, Norway

[illegible]

# Introduction of Speakers



## Cecilia Brain, Sweden

Cecilia Brain is clinically active at the Psychiatric Clinic, Sahlgrenska University Hospital. Her main field of interest is Assertive Outreach and early intervention (according to the ACT-model) in schizophrenia and other psychotic disorders in an outpatient clinic downtown Gothenburg, Sweden.

She also promotes the implementation of evidence based psychiatric care, Integrated Care Practice and Case Management in Sweden. As part of her PhD studies Cecilia Brain has initiated research within the area of Adherence in schizophrenia. The focus of her theses will be Adherence to medication in schizophrenia with special attention paid to cognition and stigma, the COAST-study. She is a frequent lecturer within her field of expertise and has established several international research networks, such as with the WPA and Institute of Psychiatry, London, as part of collaborative studies.

Cecilia Brain has been a member of national and international expert groups and advisory boards for BMS, Janssen- Cilag and Eli Lilly. She has been involved in pharmaceutical studies both as investigator and principal investigator for Lundbeck, Eli Lilly and Janssen- Cilag. She has previously received unrestricted grants from AstraZeneca, Lundbeck, Janssen- Cilag and Eli Lilly.

Cecilia Brain, M.D., doctoral candidate  
Department of Psychiatry and Neurochemistry  
The Sahlgrenska Academy, University of Gothenburg  
and  
Senior consultant, specialist in psychiatry  
Sahlgrenska University Hospital, Göteborg, Sweden  
[cecilia.brain@vgregion.se](mailto:cecilia.brain@vgregion.se)



[illegible]



## Hannu Koponen, Finland

Professor Hannu Koponen has been previously working in the Department of Psychiatry between 2001 and 2005 and currently in the department of Psychiatry, University of Eastern Finland, Kuopio, Finland. His scientific interest relates to psychiatric epidemiology, schizophrenia and psychopharmacology, and he has authored 140 original papers in these fields.

[illegible]



## Werner Kissling, Germany

Werner Kissling is Attending Psychiatrist and Head of the Center for Disease Management at the University Hospital of Munich (TU), Germany. He completed his residency in psychiatry at the Max Planck Institute of Psychiatry, Clinical Institute, Department of Psychiatry, Munich (1977–1980). Dr Kissling was Organiser of the International Consensus Conference on Guidelines for Neuroleptic Relapse Prevention in Schizophrenia, Bruges, Belgium, and Editor of the 'Guidelines for Neuroleptic Relapse Prevention in Schizophrenia' (Springer, 1991). He has been the Principal Investigator on more than 50 phase III studies and 30 clinical studies. Dr Kissling has published over 200 papers on various subjects including psychopharmacology, medical decision making, meta-analyses, shared decision making, compliance programmes and health economics. Dr Kissling was a co-author of the 'Guidelines for depot antipsychotic treatment in schizophrenia' (Kane JM et al. Eur Neuropsychopharmacol 1998;8:55–66)

Blank lined paper for writing.





## Xavier Amador, USA

Dr Amador is Adjunct professor in clinical Psychology, Columbia university, Teachers college, New York City, USA, founder and president of the LEAP institute and president of Amador and Associates, LLC, providing forensic and corporate psychological assessments for broadcast media. He obtained both his master degree and PhD in clinical psychology from new York University, Director for the alliance of the mentally ill and Director of Psychology at the New York state Psychiatric institute. An expert in clinical and forensic psychology. Dr Amador has been a consultant to numerous companies and government agencies, including the National Institute of Health, a principal investigator or co-investigator on numerous studies, Co-chair to the Schizophrenia and Related Disorders section of the DSM-IV-TR (APA, 2000) and the recipient of many prestigious awards. He serves on the editorial boards of Clinical Schizophrenia and Related Psychoses and Schizophrenia Digest. Dr Amador is the author or co-author of over 100 peer-reviewed scientific articles, 10 books and numerous book chapters.

[illegible]

# Brainstorming Session led by

Olli Kampman

## **Adherence challenge 1**

How to deal with substance abuse in schizophrenia?

Anders Berntsson

## **Adherence challenge 2**

How do we organize our care indoor/outdoor for the patient with psychotic diseases for best Adherence? Especially for the first episode patient.

Ole Andreassen

## **Adherence challenge 3**

How can we better help the patient when someone lacks insight and cognitive disturbances?

Cecilia Brain and Anders Gaasland

## **Adherence challenge 4**

Do we stumble over stigma in our daily practice or do we contribute to a fresh new set of positive attitudes to schizophrenia?



Blank lined paper for writing.



Please visit Nordic Psychiatry Academy homepage  
to get access to all this year's materials and also  
materials and videos from previous NPA events:  
**[www.jc-npa.com](http://www.jc-npa.com)**

Janssen-Cilag A/S  
Hammerbakken 19  
3460 Birkerød  
Tlf 45 94 82 82  
Fax 45 94 82 83  
[www.janssen-cilag.dk](http://www.janssen-cilag.dk)

Janssen-Cilag Oy  
Vaisalandie 2  
02130 Espoo  
Puh 0207 531 300  
Fax 0207 531 301  
[www.janssen-cilag.fi](http://www.janssen-cilag.fi)

Janssen-Cilag AS  
Postboks 144  
1325 Lysaker  
Tel 24 12 65 00  
Fax 24 12 65 10  
[www.janssen-cilag.no](http://www.janssen-cilag.no)

Janssen-Cilag AB  
Box 7073  
SE-192 07 Sollentuna  
Tel 08-626 50 00  
Fax 08-626 51 00  
[www.janssen-cilag.se](http://www.janssen-cilag.se)

**Beginning January 2011, we are changing our logo and launching a new identity for our company.**

Across the world, many of our businesses are already well known under the name of Janssen. This change unites the Janssen Pharmaceutical Companies of Johnson & Johnson under globally consistent visual image that communicates our optimism for the future.

Moving to a common identity will help us develop closer relationships among our companies to increase our opportunities to collaborate and share research. This will help us to develop innovative ideas, and integrated health care solutions for patients and customers throughout the world.

Watch for our new logo in our marketing materials, packaging, labels and regulatory filings. The names of our prescription products will remain the same.

JC-100634-1

Janssen-Cilag A/S  
Janssen-Cilag Oy  
Janssen-Cilag AS  
Janssen-Cilag AB

